PALISADE BIO INC
PALINASDAQπ #3649 by market capEarnings Mar 18 Β· PostUS Equity
$0.85βΌ $0.08 (β8.70%)
Market closed Β· at closeTrack PALI
Get earnings, price moves & breaking news on Telegram
24hβΌ 8.7%
7dβΌ 23.8%
14dβΌ 25.2%
30dβΌ 36.2%
ytdβΌ 64.0%
1yβΌ 60.0%
π¦Market Cap
$148M
Small Cap
πRevenue Growth (YoY)
β
πGross Margin
β
π΅FCF Margin
β
βοΈP/S Ratio
301.2x
Expensive
Otter Score
β
Insufficient data
Trading Snapshot
- Day Range
- $0.84 β $0.96
- 52-Week Range
- $0.84 β $2.86
- Volume (shares)
- 167,669
- Avg Volume (shares)
- β
- Shares Outstanding
- 174.3M
- Next Earnings
- 2027-03-18
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- β
- P/E Ratio
- β
- P/S Ratio
- 301.2x
- EPS (TTM)
- $-0.64
- Dividend Yield
- β
- Dilution (1yr)
- +551.9%
PALISADE BIO INC
PALIFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
β$18Mβ² +21.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
β$11MβΌ β11.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
55.7Mβ² +551.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$133Mβ² +$124M YoY
About PALISADE BIO INC
Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, advancing, and bringing to market orally administered treatments for significant conditions stemming from a compromised gastrointestinal mucosal barrier. The company's primary therapeutic candidate, LB1148, is an oral liquid formulation designed to inhibit digestive enzymes. Its goal is to safeguard gut integrity when the intestine experiences stress due to factors such as diminished blood supply, infections, or surgical procedures. Established in 2005, the company maintains its headquarters in Carlsbad, California.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
βοΈValuationβ
β
β
β
β
β‘Momentumβ
β
β
β
β
π§Dilutionβ
β
β
β
β
Overall Score
Insufficient data
β/100
Analyst Ratings
βConsensus
Buy
17 analysts
Strong Buy6
Buy10
Hold1
Sell0
Strong Sell0
Ratings as of Nov 2026
Latest News & Updates
News unavailable.